Fol. Biol. 2013, 59, 26-31

https://doi.org/10.14712/fb2013059010026

In Vivo Growth of Mantle Cell Lymphoma Xenografts in Immunodeficient Mice Is Positively Regulated by VEGF and Associated with Significant Up-regulation of CD31/PECAM1

Jan Molinský1,2, M. Klánová1,2, B. Maswabi2, T. Soukup3, M. Trněný1,4, E. Nečas2, J. Živný2, P. Klener1,2

11st Department of Medicine – Department of Haematology, First Faculty of Medicine, Charles University in Prague and General University Hospital, Prague, Czech Republic
2Institute of Pathological Physiology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic
3Department of Histology and Embryology, Medical Faculty in Hradec Králové, Charles University in Prague, Hradec Králové, Czech Republic
4Institute of Haematology and Blood Transfusion, Prague, Czech Republic

Received October 2012
Accepted October 2012

References

1. Akers, S. M., O’Leary, H. A., Minnear, F. L., Craig, M. D., Vos, J. A., Coad, J. E. , Gibson, L. F. (2010) VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers. Exp. Hematol. 38, 733-743. <https://doi.org/10.1016/j.exphem.2010.05.001>
2. Boyd, R. S., Jukes-Jones, R., Walewska, R., Brown D., Dyer, M. J. S., Cain, K. (2009) Protein profiling of plasma membranes defines aberrant signaling pathways in mantle cell lymphoma. Mol. Cell Proteomics 8, 1501-1515. <https://doi.org/10.1074/mcp.M800515-MCP200>
3. Eve, H. E., Carey, S., Richardson, S. J., Heise, C. C., Mamidipudi, V., Shi, T., Radford, J. A., Auer, R. L., Bullard, S. H., Rule, S. A. J. (2012) Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br. J. Haematol. 159, 154-163. <https://doi.org/10.1111/bjh.12008>
4. Fang, S., Repo, H., Joensuu, H., Orpana, A., Salven, P. (2011) High serum angiogenin at diagnosis predicts for failure on long-term treatment response and for poor overall survival in non-Hodgkin lymphoma. Eur. J. Cancer. 47, 1708-1716. <https://doi.org/10.1016/j.ejca.2011.02.018>
5. Fragoso, R., Pereira, T., Wu, Y., Zhu, Z., Cabeçadas, J., Dias, S. (2006) VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107, 1608-1616. <https://doi.org/10.1182/blood-2005-06-2530>
6. Gallay, N., Anani, L., Lopez, A., Colombat, P., Binet, C., Domenech, J., Weksler, B. B., Malavasi, F., Herault, O. (2007) The role of platelet/endothelial cell adhesion molecule-1 (CD31) and CD38 antigens in marrow microenvironmental retention of acute myelogenous leukemia cells. Cancer Res. 67, 8624-8632. <https://doi.org/10.1158/0008-5472.CAN-07-0402>
7. Guo, D. L., Zhang, J., Yuen, S. T., Tsui, W. Y., Chan, A. S. Y., Ho, C., Ji, J., Leung, S. Y., Chen, X. (2006) Reduced expression of EphB2 that parallels invasion and metastasis in colorectal tumours. Carcinogenesis 27, 454-464. <https://doi.org/10.1093/carcin/bgi259>
8. Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L., Coiffier, B. (2009) Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 27, 3822-3829. <https://doi.org/10.1200/JCO.2008.20.7977>
9. Jackson, D. E. (2003) The unfolding tale of PECAM-1. FEBS Lett. 540, 7-14. <https://doi.org/10.1016/S0014-5793(03)00224-2>
10. Jubb, A. M., Zhong, F., Bheddah, S., Grabsch, H. I., Frantz, G. D., Mueller, W., Kavi, V., Quirke, P., Polakis, P., Koeppen, H. (2005) EphB2 is a prognostic factor in colorectal cancer. Clin. Cancer Res. 11, 5181-5187. <https://doi.org/10.1158/1078-0432.CCR-05-0143>
11. Kurtova, A. V., Tamayo, A. T., Ford, R. J., Burger, J. A. (2009) Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113, 4604-4613. <https://doi.org/10.1182/blood-2008-10-185827>
12. Lazarova, P., Wu, Q., Kvalheim, G., Suo, Z., Haakenstad, K. W., Metodiev, K., Nesland, J. M. (2006) Growth factor receptors in hematopoietic stem cells: EPH family expression in CD34+ and CD133+ cell populations from mobilized peripheral blood. Int. J. Immunopathol. Pharmacol. 19, 49-56. <https://doi.org/10.1177/205873920601900105>
13. Lugli, A., Spichtin, H., Maurer, R., Mirlacher, M., Kiefer, J., Huusko, P., Azorsa, D., Terracciano, L., Sauter, G., Kallioniemi, O. P., Mousses, S., Tornillo, L. (2005) EphB2 expression across 138 human tumor types in a tissue microarray: High levels of expression in gastrointestinal cancers. Clin. Cancer Res. 11, 6450-6458. <https://doi.org/10.1158/1078-0432.CCR-04-2458>
14. Mahtouk, K., Tjin, E. P. M., Spaargaren, M., Pals, S. T. (2010) The HGF/MET pathway as target for the treatment of multiple myeloma and B-cell lymphomas. Biochim. Biophys. Acta 1806, 208-219.
15. Medina, D. J., Goodell, L., Glod, J., Gélinas, C., Rabson, A. B., Strair, R. K. (2012) Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor κB pathways. Haematologica 97, 1255-1263. <https://doi.org/10.3324/haematol.2011.040659>
16. Morschhauser, F., Seymour, J. F., Kluin-Nelemans, H. C., Grigg, A., Wolf, M., Pfreundschuh, M., Tilly, H., Raemaekers, J., van ‘t Veer, M. B., Milpied, N., Cartron, G., Pezzutto A., Spencer, A., Reyes, F., Dreyling, M. (2008) A phase II study of enzastaurin, a protein kinase C β inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann. Oncol. 19, 247-253. <https://doi.org/10.1093/annonc/mdm463>
17. Pérez-Galán, P., Dreyling, M., Wiestner, A. (2011) Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 117, 26-38. <https://doi.org/10.1182/blood-2010-04-189977>
18. Poggi, A., Prevosto, C., Catellani, S., Rocco, I., Garuti, A., Zocchi, M. R. (2010) Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. Br. J. Haematol. 151, 252-264. <https://doi.org/10.1111/j.1365-2141.2010.08343.x>
19. Sikkema, A. H., den Dunnen, W. F., Hulleman, E., van Vuurden, D. G., Garcia-Manero, G., Yang, H., Scherpen, F. J., Kampen, K. R., Hoving, E. W., Kamps, W. A., Diks, S. H., Peppelenbosch, M. P., de Bont, E. S. (2012) EphB2 activity plays a pivotal role in pediatric medulloblastoma cell adhesion and invasion. Neuro Oncol. 14, 1125-1135. <https://doi.org/10.1093/neuonc/nos130>
20. Smedby, K. E., Hjalgrim, H. (2011) Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin. Cancer Biol. 21, 293-298. <https://doi.org/10.1016/j.semcancer.2011.09.010>
21. Smith, S. M., van Besien, K., Karrison, T., Dancey, J., McLaughlin, P., Younes, A., Smith, S., Stiff, P., Lester, E., Modi, S., Doyle, L. A., Vokes, E. E., Pro, B. (2010) Temsirolimus has activity in non-mantle cell non-Hodgkin’s lymphoma subtypes: The University of Chicago phase II consortium. J. Clin. Oncol. 28, 4740-4746. <https://doi.org/10.1200/JCO.2010.29.2813>
22. Stopeck, A. T., Unger, J. M., Rimsza, L. M., Bellamy, W. T., Iannone, M., Persky, D. O., Leblanc, M., Fisher, R. I., Miller, T. P. (2009) A phase II trial of single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma: Southwest oncology group study S0108. Leuk. Lymphoma 50, 728-735. <https://doi.org/10.1080/10428190902856808>
23. Tsutsui, J., Kadomatsu, K., Matsubara, S., Nakagawara, A., Hamanoue, M., Takao, S., Shimazu, H., Ohi, Y., Muramatsu, T. (1993) A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms’ tumor and other human carcinomas. Cancer Res. 53, 1281-1285.
24. Wang, E. S., Teruya-Feldstein, J., Wu, Y., Zhu, Z., Hicklin, D. J., Moore, M. A. S. (2004) Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. Blood 104, 2893-2902. <https://doi.org/10.1182/blood-2004-01-0226>
25. Wang, L., Shi, W. Y., Wu, Z. Y., Varna, M., Wang, A. H., Zhou, L., Chen, L., Shen, Z. X., Lu, H., Zhao, W. L., Janin, A. (2010) Cytostatic and anti-angiogenic effects of temsirolimus in refractory mantle cell lymphoma. J. Hematol. Oncol. 3, 30-33. <https://doi.org/10.1186/1756-8722-3-30>
26. Witzig, T. E., Vose, J. M., Zinzani, P. L., Reeder, C. B., Buckstein, R., Polikoff, J. A., Bouabdallah, R., Haioun, C., Tilly, H., Guo, P., Pietronigro, D., Ervin-Haynes, A. L., Czuczman, M. S. (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann. Oncol. 22, 1622-1627. <https://doi.org/10.1093/annonc/mdq626>
27. Yoshimatsu, Y., Yamazaki, T., Mihira, H., Itoh, T., Suehiro, J., Yuki, K., Harada, K., Morikawa, M., Iwata, C., Minami, T., Morishita, Y., Kodama, T., Miyazono, K., Watabe, T. (2011) Ets family members induce lymphangiogenesis through physical and functional interaction with Prox1. J. Cell. Sci. 124, 2753-2762. <https://doi.org/10.1242/jcs.083998>
28. Zou, J. X., Wang, B., Kalo, M. S., Zisch, A. H., Pasquale, E. B., Ruoslahti, E. (1999) An Eph receptor regulates integrin activity through R-Ras. Proc. Natl. Acad. Sci. USA 96, 13813-13818. <https://doi.org/10.1073/pnas.96.24.13813>
front cover

ISSN 0015-5500 (Print) ISSN 2533-7602 (Online)

Open access journal

Submissions

Archive